YahooAugust 13, 2026 at 3:02 AM NY22 days ago

CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches

CVRx (NASDAQ:CVRX) outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity’s 46th Annual Growth Conference. President and CEO Kevin Hykes sa

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Read at Source

Companies in This Story

HUMHumana Inc401.54− 1.23%

Companies in This Story

Related Stories